4.6 Article

Definition of major bleeding: Prognostic classification

期刊

JOURNAL OF THROMBOSIS AND HAEMOSTASIS
卷 18, 期 11, 页码 2852-2860

出版社

WILEY
DOI: 10.1111/jth.15048

关键词

anticoagulants; bleeding; classification; hemorrhage; mortality

向作者/读者索取更多资源

Background In patients on anticoagulant treatment, the major bleeding (MB) definition released by the International Society of Thrombosis and Haemostasis (ISTH) is widely accepted. However, this definition identifies MBs with highly variable short-term risk of death. Objectives The study aims were to derive and validate a classification of ISTH-defined MBs for the risk of short-term death. Methods Consecutive patients admitted for ISTH-defined MB occurring while on treatment with oral anticoagulants were included in the study and divided into a derivation and a validation cohort. Death within 30 days was the primary study outcome. Results Among 1077 patients with MB, 64/517 and 63/560 patients in the derivation and validation cohort died, respectively. In the derivation cohort, Glasgow coma scale (GCS) <14 and shock were predictors of death; critical site bleeding and hemoglobin decrease >= 2 g/dL, or transfusion >= 2 units were not. GCS <14 (hazard ratio [HR], 8.67; 95% confidence interval [CI], 3.93-19.13) was predictor of death in intracranial hemorrhage (ICH) and shock at admission (HR, 4.84; 95% CI, 2.01-11.70) and pericardial bleeding (HR, 11.37; 95% CI, 1.33-97.31) in non-ICH MBs. The predictive value of GCS <14 in ICH and shock and pericardial bleeding in non-ICH MBs was confirmed in the validation cohort. None of the patients with isolated ocular or articular bleeding died. A prognostic classification of ISTH-defined MBs for the risk of short-term death is proposed as serious, severe, and life-threatening (ICH with GCS <14 or non-ICH with shock) MBs. Conclusion According to our study, ISTH-defined MBs can be stratified for the risk of death within 30 days.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据